The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.
At the second virtual session of the AACR annual meeting, researchers also discussed how they're using CRISPR to develop better cancer models and reprogram T cells.
COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.
